[HTML][HTML] Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells
Haematologica, 2010•ncbi.nlm.nih.gov
Background Multiple myeloma is an incurable malignancy of bone marrow plasma cells.
Progression of multiple myeloma is accompanied by an increase in bone marrow
angiogenesis. Studies from our laboratory suggest a role for the CXCL12 chemokine in this
process, with circulating levels of CXCL12 correlating with bone marrow angiogenesis in
patients with multiple myeloma. While the mechanisms responsible for aberrant plasma cell
expression of CXCL12 remain to be determined, studies in other systems suggest a role for …
Progression of multiple myeloma is accompanied by an increase in bone marrow
angiogenesis. Studies from our laboratory suggest a role for the CXCL12 chemokine in this
process, with circulating levels of CXCL12 correlating with bone marrow angiogenesis in
patients with multiple myeloma. While the mechanisms responsible for aberrant plasma cell
expression of CXCL12 remain to be determined, studies in other systems suggest a role for …
Abstract
Background
Multiple myeloma is an incurable malignancy of bone marrow plasma cells. Progression of multiple myeloma is accompanied by an increase in bone marrow angiogenesis. Studies from our laboratory suggest a role for the CXCL12 chemokine in this process, with circulating levels of CXCL12 correlating with bone marrow angiogenesis in patients with multiple myeloma. While the mechanisms responsible for aberrant plasma cell expression of CXCL12 remain to be determined, studies in other systems suggest a role for hypoxia and hypoxia-inducible transcription factors.
ncbi.nlm.nih.gov